Product
PEG-IFNα
Aliases
pegylated interferon alfa
3 clinical trials
3 indications
Indication
Chronic Hepatitis BIndication
Hepatitis BIndication
ChronicClinical trial
A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and Pegylated Interferon Alpha (PEG-IFNα) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) InfectionStatus: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants With Chronic Hepatitis B Infection (PREVAIL)Status: Active (not recruiting), Estimated PCD: 2026-03-01
Clinical trial
A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus InfectionStatus: Recruiting, Estimated PCD: 2027-06-01